Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436967 | 0.87 | RAB9A (0.36) | RAB9ANPC1MEN1KMT2A | |
| SCHEMBL18949082 | 0.84 | CDC7 (0.34) | MAPK1CDC7PLK4DCLK1MAPK13 | |
| SCHEMBL10147191 | 0.84 | RAB9A (0.38) | DAPK3JAK2ROCK2CDK2MARK3 | |
| SCHEMBL12231974 | 0.81 | PPARA (0.44) | RAB9ANOS2MAPT | |
| SCHEMBL10119383 | 0.81 | PPARA (0.35) | MAPT | |
| SCHEMBL10120992 | 0.80 | S1PR1 (0.45) | MAPK1CDC7PLK4DCLK1MAPK13 | |
| SCHEMBL11928813 | 0.77 | RAB9A (0.39) | MAPK1CDC7PLK4DCLK1MAPK13 | |
| SCHEMBL5287165 | 0.75 | NOTUM (0.41) | MAPK1CDC7PLK4DCLK1MAPK13 | |
| SCHEMBL3350172 | 0.75 | MAPK1 (0.41) | MAPK1CDC7PLK4DCLK1MAPK13 | |
| SCHEMBL20427474 | 0.74 | RAB9A (0.49) | MAPK1CDC7PLK4DCLK1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8785487-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | MAPK1 3682/4885CDC7 1221/4885PLK4 3471/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | MAPK1 3677/4885CDC7 1180/4885PLK4 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.